A Crohn's & IBD programme at an EU clinic such as our partner Stem Plus (Sofia) is typically €3,000–€8,000 for treatment — a fraction of US or German pricing, at full European GMP standards. Some patients access treatment at no cost through one of the 89 registered Crohn's & IBD trials — see the candidacy check first.
Crohn's disease and ulcerative colitis (inflammatory bowel disease, IBD) involve chronic intestinal inflammation driven by aberrant immune responses to commensals and barrier dysfunction. Current therapies (aminosalicylates, corticosteroids, biologics) suppress inflammation but do not repair underlying mucosal defects or fully restore immune tolerance. Stem cell strategies exploit the immunoregulatory capacity of placental mesenchymal stem cells (MSCs), which secrete anti-inflammatory cytokines (IL-10, TGF-β) and promote regulatory T cell differentiation. MSCs also enhance barrier integrity by supporting tight-junction proteins and promoting mucosal healing. A particularly important development: darvadstrocel, an allogeneic MSC product, recently obtained European Union conditional approval for treatment of complex perianal Crohn's fistulae—marking the first regulatory recognition of cell therapy for IBD. Beyond this niche indication, systemic MSC therapy for induction remission and maintenance is investigational across 89 registered trials globally; thirteen actively recruit.
Darvadstrocel for perianal fistulae costs approximately €7,000–9,500 per application in European centres. Systemic MSC induction therapy for active Crohn's or ulcerative colitis costs €6,000–8,000 per infusion protocol. Multiple fistulae or combined induction+maintenance regimens escalate costs to €12,000–20,000+ per year. Insurance coverage varies significantly: EU approved indication (perianal fistulae) is reimbursed by several national healthcare systems (Spain, France, Germany) with prior authorisation; systemic IBD remission therapy is rarely covered, classified as investigational. Out-of-pocket payment is standard for non-fistula indications.
Darvadstrocel (Alofisel) received EU conditional marketing authorisation in 2018 for complex perianal fistulising Crohn's disease refractory to conventional and biologic therapy. Pivotal trials reported fistula healing (absence of drainage from all treated fistulae) in 50–55% of patients at 24 weeks, versus ~30% in sham controls. This remains the only EU-approved cell therapy for IBD. For systemic induction therapy, published trials of intravenous MSC infusion in active Crohn's or ulcerative colitis report clinical remission in 40–55% at 8–12 weeks, comparable to biologic induction but with longer onset (8–12 weeks versus 2–4 weeks for TNF inhibitors). Mucosal healing (endoscopic resolution of ulceration) is less frequently achieved than symptom remission. Long-term maintenance data are sparse; re-induction or re-infusion protocols are emerging.
| Location | Indicative treatment cost | Regulation |
|---|---|---|
| Bulgaria (EU) · e.g. Stem Plus | €3,000–€8,000 | EU · GMP |
| Germany | €15,000–35,000 | EU · premium |
| USA | €18,000–35,000 | Mostly investigational |
| Serbia (e.g. Swiss Medica) | €7,000–31,000 | Non-EU |
| Mexico | €3,000–12,000 | Non-EU |
| Turkey / Thailand | €5,000–18,000 | Non-EU |
Bulgaria's price reflects lower operating cost inside the same EU GMP framework as Germany — not lower quality. Cell type, number of sessions and supportive care move where a Crohn's & IBD programme sits in the €3,000–€8,000 range; you receive a fixed written quote after a medical review. The cheapest monitored route of all is a registered clinical trial — check before paying privately. Watch for hidden "cell-expansion" or repeat-cycle fees billed separately.
Lower operating cost and jurisdiction — not lower quality. Bulgaria is a full EU member, so cells are prepared to the same GMP standard as Germany, but clinic overheads and salaries are far lower. That gap, not a quality compromise, is where the saving comes from.
Cheaper is not automatically riskier — but unregulated is. The real test is GMP certification, a certified cell bank and EU oversight, which the EU provides. Be wary of ultra-low prices from clinics that will not document their laboratory or their cells.
The €3,000–€8,000 range covers the medical programme. Add flights, hotel and recovery with our calculator for your true all-in cost from your city.
A fixed written quote follows a medical review of your records — so there are no surprise charges later.
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Indicative ranges for planning, compiled from public market data; confirmed pricing follows a medical review. Not medical advice.
רפואה רגנרטיבית מאושרת GMP בלב האיחוד האירופי — החל מ-3,000–8,000 יורו, חלק קטן ממחירי ארהב או גרמניה. פרוטוקולים מותאמים אישית למטופלים מ-50+ מדינות.
בדיקה רפואית חינם